SCHEMBL17629958

SCHEMBL17629958

CS(=O)(=O)OCCCc1cc(-n2ccnc2)ccc1-c1ccc(C#N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.48
PDE1A P54750 1/20 0.48
PDE1B Q01064 1/20 0.48
PDE3B Q13370 1/20 0.48
PDE1C Q14123 1/20 0.48
PDE3A Q14432 1/20 0.48
ADH5 P11766 6/20 0.44
CYP19A1 P11511 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CYP3A4 P08684 4/20 0.38
CYP2D6 P10635 4/20 0.38
CYP2C9 P11712 4/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17643465 0.84 ADH5 (0.50) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17630146 0.83 PDE2A (0.47) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17630120 0.82 PDE2A (0.47) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17643462 0.82 ADH5 (0.52) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17630020 0.81 ADH5 (0.62) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17630144 0.81 CYP2D6 (0.46) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17630062 0.81 ADH5 (0.47) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17629950 0.80 PDE2A (0.48) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17629915 0.80 ADH5 (0.47) PDE2APDE1APDE1BPDE3BPDE1C
SCHEMBL17629984 0.77 PDE2A (0.50) PDE2APDE1APDE1BPDE3BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016046782-A1 IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2016-03-31 WO disclosed